Engineered antibody maker KaloBios takes on $20M for clinical trials

South San Francisco, Calif.-based KaloBios Pharmaceuticals, which develops non-human antibodies for use in human bodies, has taken $20 million in its fourth round of venture funding.

KaloBios is currently going through seven first- and second-phase clinical trials for two drugs and is working on a third, newer drug. The drugs are aimed at patients with cystic fibrosis and autoimmune disorders like asthma.

Mitsubishi UFJ Capital and Genzyme Ventures co-led the round. Also participating were previous investors MPM Capital, Alloy Ventures, GBS Ventures, Sofinnova Ventures, Singapore Bioinnovations, 5AM Ventures and Lotus Bioscience Ventures.